A substituted diaryl urea derivative and its preparation method and application
By developing a small molecule compound with novel structure, it significantly inhibits the proliferation of human liver cancer, gastric cancer and breast cancer cells, solves the problem of limited inhibition effect of existing anti-cancer drugs on these cancer cells, and provides a new anti-cancer Treatment plan.
Patent Information
- Application Number
- CN202110559295.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-05-21
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2041-05-21
AI Technical Summary
Existing anti-cancer drugs show limited inhibitory effects on certain types of cancer cells, especially the proliferation activities of human liver cancer cells HepG2, human gastric cancer cells MGC803, and human breast cancer cells MCF 7, and lack effective targeted treatments. plan.
A small molecule compound with novel structures, having a compound of formula (I) or an optical isomer, cistrans isomer or pharmaceutically acceptable salt thereof, was developed for the preparation of antitumor drugs by inhibiting these cancers. Cell growth and proliferation.
This compound significantly inhibits the proliferation activities of human liver cancer cells HepG2, human gastric cancer cell MGC803 and human breast cancer cell MCF 7, and has good growth inhibitory activity on human umbilical vein endothelial cell HUVEC, providing a new anti-cancer treatment plan .
Smart Images

Figure CN113264874B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a substituted diaryl urea derivative and a preparation method and application thereof. Background Art
[0002] Malignant tumors, also known as cancer, are usually caused by abnormal mechanisms controlling cell growth and proliferation. The continued growth, migration and invasion of tumors are inseparable from the nutrient supply of new blood vessels. The formation of new blood vessels plays an important role in the occurrence, development and metastasis of tumors. Tumor angiogenesis is a common feature of all solid tumors. Data show that the growth and metastasis of malignant tumors must rely on rich nutrient supply. Without angiogenesis, the growth volume of tumor tissue cultured in vitro does not exceed 4mm 3 The tumor in the body does not exceed 1 to 2 mm 3 . Vascular endothelial growth factor (VEGF) and its receptor VEGFR can specifically promote the division, proliferation and migration of endothelial cells, and play an important role in the process of tumor angiogenesis. Therefore, VEGF and VEGFR have become the most widely used targets for cancer treatment. In recent years, chemical small molecule targeted drugs have developed rapidly, and it is urgent to find new small molecule drugs and explore new targets. Summary of the invention
[0003] The purpose of the present invention is to provide a small molecule anticancer compound with a novel structure.
[0004] The first aspect of the present invention provides a compound having a structure represented by general formula (I), or an optical isomer, cis-trans isomer or pharmaceutically acceptable salt thereof:
[0005]
[0006] Wherein, Y is O or S;
[0007] is substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 5-7 Cycloalkenyl, substituted or unsubstituted C 4-7 Heterocyclyl, substituted or unsubstituted 4-10 membered heteroaryl;
[0008] is substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 5-7 Cycloalkenyl, substituted or unsubstituted C 4-7 Heterocyclyl, substituted or unsubstituted 4-10 membered heteroaryl;
[0009] is substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 5-7 Cycloalkenyl, substituted or unsubstituted C 3-7 Heterocyclyl, substituted or unsubstituted 4-10 membered heteroaryl;
[0010] is substituted or unsubstituted C 6-10 Aryl, substituted or unsubstituted C 3-6 Cycloalkyl, substituted or unsubstituted C 5-7 Cycloalkenyl, substituted or unsubstituted C 3-7 Heterocyclyl, substituted or unsubstituted 4-10 membered heteroaryl;
[0011] The substitution refers to substitution by one or more substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, phenyl, carboxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, -NR aa R bb ,-COOC 1-6 Alkyl, -COC 1-6 Alkyl, -CONR aa R bb ;
[0012] Among them, R aa , R bb Independently selected from: hydrogen, C 1-6 Alkyl, hydroxyl, C 3-6 Cycloalkyl, C 4-7 Heterocyclic group.
[0013] m is 1, 2, 3, 4, 5, 6, 7 or 8;
[0014] Each L is independently a group selected from the group consisting of a covalent bond, -CH2-, -NR'-, -O-, -S-, -SO2-, -COO-, -CONH-, -CO-, thiocarbonyl-amino Thiocarbonyl-amino-carbonyl When n≥2, each L can be the same or different; R' is H or C 1-6 alkyl.
[0015] is unsubstituted or substituted phenyl, wherein the substitution refers to substitution by one or more substituents selected from the group consisting of halogen, amino, nitro, cyano, hydroxyl, phenyl, carboxyl, C 1-6 Alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl.
[0016] In another preferred embodiment, ring A is In the formula, R a H, C 1-4 Haloalkyl, F, Cl, Br or methyl; R b H or C 1-4 Haloalkyl; R c H, C 1-4 haloalkyl, nitro, F, Cl, Br, methyl, methoxy, amino or hydroxy; R d H, C 1-4 haloalkyl, nitro, F, Cl, Br, methyl, methoxy, amino or hydroxy; R e H, C 1-4 In another preferred embodiment, R b , R c , R d is hydrogen; R a , R e It is a halogen (fluorine, chlorine, bromine, iodine).
[0017] In another preferred embodiment, is a substituted or unsubstituted 4-10 membered heteroaryl group selected from the following structures:
[0018]
[0019] In various types, R 1 , R 2 , R 3 , R 4 Each independently selected from: H, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, nitro, F, Cl, Br, amino, hydroxy.
[0020] In another preferred embodiment, R 1 , R 3 , R 4 H; R 2 Selected from: H, C 1-4 alkyl.
[0021] In another preferred embodiment, Select from the following structures:
[0022]
[0023] In the formula, R 6 , R7 , R 8 , R 9 are independently hydrogen, halogen, nitro, cyano, hydroxyl, phenyl, carboxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl;
[0024] X is O, S or NH.
[0025] In the present invention, the wavy line indicates the connection. The uppermost wavy line indicates the connection with [L], and the other wavy line indicates the connection with NH.
[0026] In another preferred embodiment, Select from the following group:
[0027]
[0028] In the formula, R 6 , R 7 , R 8 , R 9 Each is independently hydrogen or halogen.
[0029] In another preferred embodiment, for In the formula, R 6 , R 7 , R 8 , R 9 Each is independently hydrogen or halogen. In another preferred embodiment, R 6 , R 7 , R 8 , R 9 For hydrogen.
[0030] In another preferred embodiment, for In the formula, R 6 , R 7 , R 8 , R 9 Each is independently hydrogen or halogen. In another preferred embodiment, R 7 , R 8 are each independently hydrogen, R 6 , R 9 Each is independently hydrogen, fluorine, chlorine or trifluoromethyl.
[0031] In another preferred embodiment, Select from the following structures:
[0032]
[0033] In the formula, R 10 , R 11 , R 12 , R 13 Each is independently hydrogen or halogen.
[0034] In the present invention, the wavy line indicates the connection. The top wavy line indicates the connection with NH, and the other wavy line indicates the connection with connection.
[0035] In another preferred embodiment, for In the formula, R 10 , R 11 , R 12 , R 13 Each is independently hydrogen or halogen. In another preferred embodiment, R 13 , R 10 are each independently hydrogen, R 11 , R 12 Each is independently hydrogen, fluorine, chlorine or trifluoromethyl.
[0036] In another preferred embodiment, is an unsubstituted or substituted group selected from the group consisting of phenyl, pyridyl, pyrimidopyrazolyl, pyrazolyl, imidazolyl, pyrrolyl, thiadiazolyl, thiazolyl, benzothiazolyl and tetrazolyl, wherein the substitution refers to substitution by one or more substituents selected from the group consisting of halogen, nitro, cyano, hydroxyl, phenyl, carboxyl, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, -NR aa R bb ,-COOC 1-4 Alkyl, -COC 1-4 Alkyl, -CONR aa R bb ;
[0037] R aa , R bb Independently selected from: hydrogen, C 1-4 alkyl.
[0038] In another preferred embodiment, Select from the following group:
[0039]
[0040] In the formula, R 14 , R 15 , R 16 , R 17 , R 18are each independently hydrogen, fluorine, chlorine, bromine, nitro, cyano, hydroxyl, phenyl, carboxyl, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, -NR aa R bb ,-COOC 1-4 Alkyl, -COC 1-4 Alkyl, -CONR aa R bb ;
[0041] R aa , R bb Independently selected from: hydrogen, C 1-4 alkyl.
[0042] In another preferred embodiment, for: R 14 , R 17 are independently hydrogen, fluorine, chlorine, bromine, nitro, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, -NR aa R bb ,-COOC 1-4 Alkyl, -COC 1-4 Alkyl, -CONR aa R bb ; R 15 , R 16 are independently hydrogen, fluorine, chlorine, bromine, nitro, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, -NR aa R bb ,-COOC 1-4 Alkyl, -COC 1-4 Alkyl, -CONR aa R bb .
[0043] R aa , R bb Independently selected from: hydrogen, C 1-4 alkyl.
[0044] In another preferred embodiment, R 14 , R 16 , R 17 are each independently hydrogen, R 15 For-CONRaa R bb ; Among them, R aa , R bb Independently selected from: hydrogen, C 1-4 alkyl.
[0045] In another preferred embodiment, for
[0046] In another preferred embodiment, the compound is any one of compounds numbered I-1 to I-293.
[0047] The second aspect of the present invention provides a pharmaceutical composition comprising the compound described in the first aspect, or an optical isomer, cis-trans isomer or pharmaceutically acceptable salt of the compound; and a pharmaceutically acceptable carrier and / or excipient.
[0048] In another preferred embodiment, the pharmaceutical composition comprises: (1) 0.001-99.99% by weight of the compound or its optical isomers, cis-trans isomers or pharmaceutically acceptable salts, or a combination thereof; and (2) a pharmaceutically acceptable carrier and / or excipient.
[0049] The third aspect of the present invention provides the use of the compound described in the first aspect, or the optical isomers, cis-trans isomers or pharmaceutically acceptable salts of the compound, or the pharmaceutical composition described in the second aspect, for preparing anti-tumor drugs.
[0050] In another preferred embodiment, the tumor is selected from: nasopharyngeal carcinoma, esophageal cancer, gastric cancer, liver cancer, breast cancer, colon cancer, prostate cancer, lung cancer, cervical cancer, leukemia, oral cancer, salivary gland tumors, nasal and paranasal sinus malignant tumors, laryngeal cancer, ear tumors, eye tumors, thyroid tumors, mediastinal tumors, chest wall, pleural tumors, small intestine tumors, biliary tract tumors, pancreatic and periampullary tumors, mesenteric and retroperitoneal tumors, kidney tumors, adrenal tumors, bladder tumors, prostate cancer, testicular tumors, penile cancer, endometrial cancer, ovarian malignant tumors, malignant trophoblastic tumors, vulvar and vaginal cancer, malignant lymphoma, multiple myeloma, soft tissue tumors, bone tumors, skin and adnexal tumors, malignant melanoma and nervous system tumors.
[0051] The fourth aspect of the present invention provides a treatment method, which comprises the steps of administering the compound described in the first aspect of the present invention or the optical isomers, cis-trans isomers or pharmaceutically acceptable salts of the compound, or the composition described in the second aspect of the present invention to a patient in need.
[0052] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. DETAILED DESCRIPTION
[0053] After long-term and in-depth research, the inventors have discovered and synthesized a series of novel compounds with significant anticancer activity. The compounds provided by the present invention show significant inhibition of the proliferation activity of human liver cancer cells HepG2, human gastric cancer cells MGC803 and human breast cancer cells MCF 7, and have good growth inhibition activity on human umbilical vein endothelial cells HUVEC. On this basis, the inventors have completed the present invention.
[0054] Group Definition
[0055] In the present invention, unless otherwise specified, the terms used have the general meanings well known to those skilled in the art.
[0056] In the present invention, the term "C1-C6" refers to having 1, 2, 3, 4, 5 or 6 carbon atoms, "C1-C4" refers to having 1, 2, 3 or 4 carbon atoms, and so on. "4-10 membered" refers to having 4-10 ring atoms, and so on.
[0057] The term "C 1-6 The term "alkyl" refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, or the like.
[0058] The term "C 2-6 The term "alkenyl" refers to a straight or branched alkenyl group having 2 to 6 carbon atoms, such as vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, or the like.
[0059] The term "C 2-6 The term "alkynyl" refers to a straight or branched chain alkynyl group having 2 to 6 carbon atoms, such as ethynyl, propynyl, or the like.
[0060] The term "C 3-6 The term "cycloalkyl" refers to a cyclic alkyl group having 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or the like.
[0061] The term "C 5-7 The term "cycloalkenyl" refers to a cyclic alkenyl group having 5 to 7 carbon atoms and having one or more double bonds, such as cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, or the like.
[0062] As used herein, the term “C 1-4 The term "alkoxy" refers to a straight or branched alkoxy group having 1 to 4 carbon atoms, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, or the like.
[0063] The term "halogen" refers to fluorine, chlorine, bromine, or iodine. The term "halogenated" refers to a group substituted by the same or different one or more halogen atoms mentioned above, for example trifluoromethyl, pentafluoroethyl, heptafluoroisopropyl, or the like.
[0064] The term "heterocycle" refers to at least one atom in the atoms forming the heterocycle skeleton that is not carbon but is nitrogen, oxygen or sulfur. Typically, the heterocycle contains no more than 5 nitrogens, no more than 2 oxygens and / or no more than 2 sulfurs. Unless otherwise indicated, the heterocycle can be a saturated, partially unsaturated or fully unsaturated ring.
[0065] In the present invention, the term "aryl" refers to a hydrocarbon moiety containing one or more aromatic rings. 10 The term "aryl" refers to an aromatic ring group having 6 to 10 carbon atoms and containing no heteroatoms in the ring, such as phenyl, naphthyl, etc.
[0066] As used herein, the term "heteroaryl" refers to a heteroaromatic system containing one or more (preferably 1, 2, 3, 4, 5 or 6) heteroatoms (selected from N, O, S), for example, a 4-10 membered heteroaryl refers to a heteroaromatic system containing 4-10 ring atoms, including but not limited to phenyl, pyridyl, pyrimidopyrazolyl, pyrazolyl, imidazolyl, pyrrolyl, thiadiazolyl, thiazolyl, benzothiazolyl, thienyl, tetrazolyl, furanyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the heteroaryl ring is linked to the parent structure.
[0067] The term "alkyl" refers to a group formed by removing one hydrogen atom from an alkane molecule; the term "alkylene" refers to a group formed by removing two hydrogen atoms from an alkane molecule. Similarly, the definitions of "alkenylene", "alkynylene", "cycloalkylene", "cycloalkenylene", "phenylene", "naphthylene", "heterocyclylene" or "heteroaromatic bicyclic or tricyclic ring system" are similar.
[0068] Unless otherwise specified as "substituted or unsubstituted", the groups of the present invention may be substituted by substituents selected from the following groups: halogen, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Halogenated alkenyl, C 2-6 Alkynyl, C 2-6Haloalkynyl, hydroxyl, hydroxyl C 1-4 Alkyl, OR', Si(R')3, NR'R", C(O)R', C(O)OR', C(O)NR'R", SR', S(O) m R', S(O)2NR'R", OC(O)R', OC(O)NR'R", OS(O)2R', OS(O)2NR'R", N(R")C(O)R', NCH2R', N(R")C(O)NR'R", N(R")S(O)2R' or N(R')S(O)2NR'R", etc., wherein R' and R" are defined as above, and m is 1 or 2.
[0069] Wherein, R' and R" are each independently H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Halogenated alkenyl, C 2-6 Alkynyl, C 2-6 Haloalkynyl, substituted or unsubstituted C 3-7 Cycloalkyl, substituted or unsubstituted C 5-7 cycloalkenyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted 5-membered or 6-membered heterocyclyl, or substituted or unsubstituted 8-membered to 12-membered heteroaromatic bicyclic ring system, wherein the substitution refers to substitution by one or more groups selected from the group consisting of halogen, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Halogenated alkenyl, C 2-6 Alkynyl, C 2-6 Haloalkynyl, hydroxyl, hydroxyl C 1-4 alkyl.
[0070] Inert solvents refer to various solvents that do not react with raw materials, including various linear, branched or cyclic alcohols, ethers or ketones, halogenated alkanes, 1,4-dioxane, acetonitrile, tetrahydrofuran, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and the like.
[0071] The term "pharmaceutically acceptable salt" refers to a salt formed by a compound of formula I of the present invention and a pharmaceutically acceptable inorganic acid or organic acid, wherein preferred inorganic acids include (but are not limited to): hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, and sulfuric acid; preferred organic acids include (but are not limited to): formic acid, acetic acid, propionic acid, succinic acid, naphthalene disulfonic acid (1,5), oxalic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, valeric acid, diethylacetic acid, malonic acid, succinic acid, fumaric acid, pimelic acid, adipic acid, maleic acid, malic acid, aminosulfonic acid, phenylpropionic acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methanesulfonic acid, p-toluenesulfonic acid, citric acid, and amino acids.
[0072] The term "optical isomer" means that the chiral carbon atom involved in the compound of the present invention can be in R configuration, S configuration, or a combination thereof. The compound of the invention may contain one or more asymmetric centers and therefore appear in the form of racemates, racemic mixtures, single enantiomers, diastereomeric compounds and single diastereomers. The asymmetric centers that may exist depend on the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers, and all possible optical isomers and diastereomeric mixtures and pure or partially pure compounds are included within the scope of the present invention. The present invention includes all isomeric forms of the compound.
[0073] Pharmaceutical compositions and methods of administration
[0074] As used herein, "composition" refers to any mixture, which may be a solution, a mixture, a liquid, a powder, an ointment, an aqueous, a non-aqueous, or any combination thereof.
[0075] The compounds of the present invention and their pharmaceutically acceptable salts or compositions containing them can be administered in unit dosage forms, and the administration routes can be divided into enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs and respiratory tract, skin, vagina, rectum, etc.
[0076] The dosage form can be a liquid dosage form, a solid dosage form or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including O / W, W / O types and multiple emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops, nasal drops, lotions, etc.; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.; semisolid dosage forms can be ointments, gels, pastes, etc.
[0077] The compounds of the present invention and pharmaceutically acceptable salts thereof can be prepared into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.
[0078] In order to prepare the compound of the present invention and its pharmaceutically acceptable salt into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and retention agents. The diluent can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent can be water, ethanol, isopropanol, etc.; the binder can be starch, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia glue, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose,
[0079] Acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; disintegrants can be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid esters, sodium dodecyl sulfate, etc.; lubricants and glidants can be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.
[0080] The tablets can also be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets. In order to make the dosing unit into a capsule, the active ingredient compound of the present invention and its pharmaceutically acceptable salt can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient compound of the present invention and its pharmaceutically acceptable salt can also be first made into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. The various diluents, binders, wetting agents, disintegrants, and glidants used to prepare tablets of the compound of the present invention and its pharmaceutically acceptable salt can also be used to prepare capsules of the compound of the present invention and its pharmaceutically acceptable salt.
[0081] In order to prepare the compound of the present invention and its pharmaceutically acceptable salt into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and a solubilizer, a cosolvent, a pH regulator, and an osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc., the pH regulator can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support agent.
[0082] Furthermore, if necessary, colorants, preservatives, perfumes, flavoring agents or other additives may be added to the pharmaceutical preparations.
[0083] In order to achieve the purpose of medication and enhance the therapeutic effect, the drug or pharmaceutical composition of the present invention can be administered by any known administration method.
[0084] The benefits of the present invention are as follows: the present invention provides a class of compounds with novel structures, and the compounds have significant activity in inhibiting the proliferation of cancer cells (including but not limited to: human liver cancer cells HepG2, human gastric cancer cells MGC803 and human colon cancer cells HCT 116);
[0085] Preparation method of the compound of the present invention
[0086] The compound shown in the general formula of the present invention can be prepared by the following method, but the conditions of the method, such as the amount of reactants, solvents, alkalis, compounds used, reaction temperature, reaction time required, etc. are not limited to the following explanation. The compounds of the present invention can also be prepared conveniently by combining various synthetic methods described in this specification or known in the art, and such a combination can be easily carried out by a technician in the field to which the present invention belongs. If feasible, the reagent can be purchased through commercial channels.
[0087] Typical embodiments of the compounds of the present invention can be synthesized using the following general reaction schemes. It is apparent from the description given herein that the general scheme can be changed by replacing with other materials with similar structures to obtain corresponding different products. The synthetic method can provide a large amount of production as required. The raw materials can be obtained by commercial methods or synthesized using disclosed methods. The examples given herein, through simple inspection steps, the characteristics of the final product usually make the characteristics of the necessary raw materials obvious.
[0088] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0089] Example 1: Synthesis of 4-(4-(3-(3-((2,6-difluorobenzyl)oxy)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0090]
[0091] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0092] Experimental steps: Under argon protection, a mixture of tert-butyl (3-hydroxyphenyl)carbamate (1.01 g, 5 mmol) and anhydrous potassium carbonate (0.69 g, 5 mmol) in acetone (10 mL) was stirred in an ice bath, and then a mixture of 2-(bromomethyl)-1,3-difluorobenzene (1.00 g, 5 mmol) in acetone (5 mL) was slowly added. The reaction mixture was reacted at room temperature for 12 hours and followed by TLC. After the reaction was completed, the solvent was removed under reduced pressure and purified by column chromatography (ethyl acetate: n-heptane = 1:4) to obtain a light yellow solid (1.25 g, 75%). 1 H NMR (400MHz, DMSO-d6) δ9.35(s,1H),7.52(m,1H),7.27–7.12(m,4H),7.06(d,J=8.0Hz,1H),6.67(dd,J=8.4,2.0Hz,1H),5.05(s,2H),1.47(s,9H). 19 F NMR (376MHz, DMSO-d6) δ-115.16 (t, J = 7.0Hz, 2F).
[0093] The tert-butyl (3-((2,6-difluorobenzyl)oxy)phenyl)carbamate obtained above was dissolved in a mixture of trifluoroacetic acid and dichloromethane (1:1), stirred at room temperature for 2 hours, and then the solvent was removed under reduced pressure to obtain the trifluoroacetate salt of the amine. Sodium hydroxide was used for alkalization, and organic solvent was used for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, and purified by column chromatography (ethyl acetate: n-heptane = 1:2) to obtain a white solid with a yield of 80%. 1 H NMR (400MHz, DMSO-d6) δ8.21(s,2H),7.53(m,1H),7.20(m,3H),6.73(dd,J=8.0,2.0Hz,1H),6.70–6.63(m,2H),5.08(s,2H). 19 F NMR (376MHz, DMSO-d6) δ-115.15 (t, J = 7.2Hz, 2F).
[0094] 4-(4-aminophenoxy)-N-methylpicolinamide (0.47g, 2mmol) was dissolved in 10mL of dichloromethane. Under ice bath conditions, a mixture of dichloromethyl carbonate (BTC) (0.59g, 2mmol) in dichloromethane (10mL) was slowly added dropwise, followed by a mixture of triethylamine (2mL) in dichloromethane (10mL), and the mixture was reacted at room temperature for 6 hours. After the reaction was completed, the solvent was removed under reduced pressure, and the obtained 4-(4-isocyanate)-N-methylpicolinamide was directly used for the next step. The above product was dissolved in anhydrous dichloromethane (10mL), and a mixture of 3-((2,6-difluorobenzyl)oxy)aniline (0.47g, 2mmol) in dichloromethane was slowly added dropwise, and the mixture was reacted at room temperature for 12 hours. After the reaction was completed, the reaction solution was removed under reduced pressure, and the product was purified by column chromatography (ethyl acetate: n-heptane = 2:1), and the obtained product was a white solid. Yield: 78%. 1 H NMR(400MHz, DMSO-d6)δ8.86(s,1H),8.82–8.73(m,2H),8.51(d,J=5.6Hz,1H),7.60(d,J=9.2Hz,2H),7.58–7.49(m,1H),7.42( d,J=2.4Hz,1H),7.30(s,1H),7.27–7.12(m,6H),7.04(d,J=8.0Hz,1H),6.73–6.67(m,1H),5.11(s,2H),2.81(d,J=4.8Hz,3H). 19 F NMR (376MHz, DMSO-d6) δ-115.05 (t, J = 7.2Hz, 2F). 13 C NMR (101MHz, DMSO) δ165.99, 163.77, 162.46 (d, J = 7.8Hz), 159.99 (d, J = 7.8Hz), 158.53,152.47(d,J=6.0Hz),150.30,147.46,140.91,137.47,131.70(t,J=10. 4Hz), 129.65, 121.41, 119.99, 113.91, 112.47 (t, J = 19.2Hz), 111.86 (dd, J = 18. 9,5.9Hz),111.31,108.66,107.84,104.96,57.56(t,J=3.3Hz),25.96.HRMS(EI + )cal.forC 27 H 22 F2N4O4(M) + 504.1609, found 504.1611.
[0095] Example 2: Synthesis of 4-(4-(3-(3-((2,6-difluorobenzyl)amino)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0096]
[0097] Reagents and conditions: a) NaBH3CN, MeOH, reflux; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0098] Experimental steps: 2,6-difluorobenzaldehyde (0.71 g, 5 mmol) was added to a methanol mixture of tert-butyl (3-aminophenyl)carbamate (1.04 g, 5 mmol). While stirring, sodium cyanoborohydride (0.88 g, 14 mmol) was added, and the reaction mixture was stirred under reflux for 4 to 6 hours. After the reaction was completed, the mixture was cooled, the methanol was distilled off under reduced pressure, and the reaction mixture was extracted with ethyl acetate (3 x 30 ml). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The mixture was purified by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain tert-butyl {3-[(2,6-difluorobenzyl)amino]phenyl}carbamate (50 mg, 40%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ9.04(s,1H),7.38(m,1H),7.08(m,2H),6.97–6.88(m,2H),6.61(d,J=8. 6Hz, 1H), 6.28 (dd, J=8.0, 1.8Hz, 1H), 5.91 (t, J=5.6Hz, 1H), 4.21 (d, J=4.4Hz, 2H), 1.46 (s, 9H). 19 F NMR (376MHz, DMSO-d6) δ-115.05 (t, J = 7.2Hz, 2F).
[0099] The above-obtained tert-butyl (3-((2,6-difluorobenzyl)amino)phenyl)carbamate was dissolved in a mixture of trifluoroacetic acid and dichloromethane (1:1), stirred at room temperature for 2 hours, and then the solvent was removed under reduced pressure to obtain the trifluoroacetate salt of the amine. Sodium hydroxide was used for alkalization, and organic solvent was used for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, and purified by column chromatography (ethyl acetate: n-heptane = 1:2) to obtain a white solid with a yield of 82%. 1 H NMR (400MHz, DMSO-d6) δ7.35(m,1H),7.12–7.01(m,2H),6.74(t,J=7.8Hz,1H),5.99–5.56(m,4H),4.77(d,J=9.2Hz,2H),4.19(s,2H).19 FNMR(376MHz,DMSO-d6)δ-115.05(t,J=7.2Hz,2F).
[0100] The obtained 4-(4-isocyanate)-N-methylpicolinamide was dissolved in anhydrous dichloromethane (10 mL), and a dichloromethane mixture of N1-(2,6-difluorobenzyl)benzene-1,3-diamine (0.47 g, 2 mmol) was slowly added dropwise, and the mixture was reacted at room temperature for 12 hours. After the reaction was completed, the reaction solution was removed under reduced pressure and purified by column chromatography (ethyl acetate: n-heptane = 2:1), and the obtained product was a white solid. Yield: 75%. Melting point: 149-150°C. 1 H NMR (400MHz, DMSO-d6) δ8.80–8.73 (m, 2H), 8.50 (d, J = 5.6Hz, 1H), 8.45 (s, 1H ),7.62–7.53(m,2H),7.44–7.36(m,2H),7.19–7.08(m,5H),6.98(t,J=8.0Hz ,1H),6.84(t,J=2.0Hz,1H),6.70(dd,J=7.8,2.0Hz,1H),6.32(dd,J=8.0,2. 2Hz, 1H), 6.00 (d, J = 5.8Hz, 1H), 4.25 (d, J = 4.4Hz, 2H), 2.80 (d, J = 4.8Hz, 3H). 19 F NMR (376MHz, DMSO-d6) δ-115.00 (t, J = 7.2Hz, 2F). 13 C NMR(101MHz,DMSO-d6)δ170.30,166.03,163.77,162.45(d,J=8.4Hz),159.99(d ,J=8.6Hz),152.41,150.31,148.75,147.26,140.24,137.71,129.83(t,J=10.4 Hz),129.14,121.41,119.72,115.08(t,J=19.3Hz),113.91,111.64(dd,J=18.9 Hz, 6.5Hz), 108.64, 106.74, 105.95, 102.23, 34.79 (t, J = 2.8Hz), 25.97.HRMS (EI + )cal.for C 27 H 23 F2N5O3(M) + 503.1769, found 503.1789.
[0101] Example 3: Synthesis of 4-(4-(3-(3-(2,6-difluorobenzamido)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0102]
[0103] Reagents and conditions: a) Et3N, DCM, 0°C; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0°C, 12h; d) DCM, Ar, 12h.
[0104] Experimental steps: Dissolve tert-butyl (3-aminophenyl)carbamate (5mmol) in dichloromethane, add triethylamine (7.5mmol), and stir under ice bath conditions. Add dichloromethane mixed solution containing 2,6-difluorobenzoyl chloride (5mmol) dropwise to the reaction solution. After the addition is complete, keep the reaction system dry and react at room temperature for 6 hours. TLC tracking, after the reaction is completed, vacuum distillation is performed to dryness, dichloromethane extraction is performed, the organic phases are combined, dried over anhydrous sodium sulfate, and purified by column chromatography (ethyl acetate: n-heptane = 1:4). It appears as a white solid with a yield of 72%. 1 H NMR(400MHz,Chloroform-d)δ8.85(s,1H),8.26(s,1H),7.90(t,J=1.9Hz,1H),7.55(t,J=8.0Hz,1H),7.44(ddd ,J=8.0,1.9,1.3Hz,1H),7.30(dt,J=8.2,1.6Hz,1H),7.23(t,J=8.1Hz,1H),7.14(d,J=7.9Hz,2H),1.43(s,9H).
[0105] The above-obtained tert-butyl (3-(2,6-difluorobenzamido)phenyl)carbamate was dissolved in a mixture of trifluoroacetic acid and dichloromethane (1:1), stirred at room temperature for 2 hours, the solvent was removed under reduced pressure, alkalized with sodium hydroxide, and extracted with an organic solvent. The organic phases were combined, dried over anhydrous sodium sulfate, and purified by column chromatography (ethyl acetate: n-heptane = 1:2) to obtain a white solid with a yield of 83%. 1 H NMR (400MHz, Chloroform-d) δ8.68 (s, 1H), 7.52–7.37 (m, 2H), 7.20–7.12 (m, 4H), 6.49 (ddd, J = 7.6, 1.9, 1.2Hz, 1H), 4.75 (s, 2H).
[0106] Dissolve N-(3-aminophenyl)-2,6-difluorobenzamide (2mmol) in anhydrous dichloromethane (10mL), slowly dropwise add 4-(4-isocyanate)-N-methylpicolinamide dissolved in anhydrous dichloromethane (10mL), and react at room temperature for 12 hours. After the reaction is completed, remove the reaction solution under reduced pressure, purify by column chromatography (ethyl acetate: n-heptane = 1:1), and the obtained product is a white solid. Yield: 70%. 1 H NMR (400MHz, DMSO-d6) δ10.79(s,1H),8.85(s,1H),8.77(m,2H),8.50(d,J=5.6Hz,1H),7.93(s,1H),7 .68–7.54(m,3H),7.39(d,J=2.4Hz,1H),7.35–7.22(m,5H),7.22–7.09(m,3H),2.79(d,J=4.8Hz,3H). 19 F NMR (376MHz, DMSO-d6) δ-114.12 (t, J = 7.2Hz, 2F). 13 C NMR (101MHz, DMSO) δ170.30, 166.00, 163.77, 160.04 (d, J = 7.8Hz), 158.08, 157.57 (d, J = 7.8Hz), 152.43 (d, J = 5.6Hz), 150.33, 147.44, 140.11, 138. 88,137.49,131.96,129.21,121.44,119.92,115.52,114.04(d,J=10.6Hz ),113.08,112.13(dd,J=18.6Hz,4.8Hz),109.31,108.66,25.97.HRMS(EI + )cal.for C 27 H 21 F2N5O4(M) + 517.1562, found 517.1598.
[0107] Example 4: Synthesis of 3-(3-(4-((2-(carbamoyl)pyridin-4-yl)oxy)phenyl)ureido)phenyl 2,6-difluorobenzoate
[0108]
[0109] Reagents and conditions: a) Et3N, THF, reflux; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0110] Experimental steps: dissolve tert-butyl (3-hydroxyphenyl)carbamate in tetrahydrofuran (THF) (20 ml), add triethylamine Et3N (1 mmol, 0.1) and stir, heat to reflux temperature, add 2,6-difluorobenzoyl chloride (1 mmol), and then continue to react with stirring at room temperature and track by TLC. After the reaction is completed, filter the precipitate and recrystallize from ethanol to obtain the target compound 2,6-difluorobenzoic acid 3-[(tert-butoxycarbonyl)amino]phenyl ester as a white solid with a yield of 80%. 1 H NMR (400MHz, DMSO-d6) δ9.63(s,1H),7.80–7.72(m,1H),7.61–7.52(m,1H),7.43–7.29(m,4H),6.93–6.87(m,1H),1.50(s,9H).
[0111] The target compound 2,6-difluorobenzoic acid 3-[(tert-butyloxycarbonyl)amino]phenyl ester obtained above was dissolved in a mixture of trifluoroacetic acid and dichloromethane (1:1), stirred at room temperature for 2 hours, and then the solvent was removed under reduced pressure to obtain the trifluoroacetate salt of the amine. Sodium hydroxide was used for alkalization and organic solvent extraction was performed. The organic phases were combined, dried over anhydrous sodium sulfate, and purified by column chromatography (ethyl acetate: n-heptane = 1:2) to obtain a white solid with a yield of 80%. 1 H NMR (400MHz, DMSO-d6) δ7.79–7.70(m,1H),7.33(t,J=8.6Hz,2H),7.11(t,J=8.0Hz,1H),6.54(dd d,J=8.2,2.0,0.8Hz,1H),6.46(t,J=2.2Hz,1H),6.36(ddd,J=8.0,2.4,0.8Hz,1H),5.41(s,2H). 19 F NMR (376MHz, DMSO-d6) δ-111.21 (dd, J=8.8, 6.4Hz, 2F).
[0112] Dissolve 4-(4-isocyanate)-N-methylpicolinamide in anhydrous dichloromethane (10 mL), slowly dropwise add a dichloromethane mixture of 3-aminophenyl 2,6-difluorobenzoate (0.47 g, 2 mmol), and react at room temperature for 12 hours. After the reaction is completed, remove the reaction solution under reduced pressure, purify by column chromatography (ethyl acetate: n-heptane = 1:1), and the obtained product is a white solid. Yield: 70%. Melting point: 94-95°C. 1H NMR (400MHz, DMSO-d6) δ9.01(s,1H),8.91(s,1H),8.80–8.76(m,1H),8.51(d,J=5.6Hz,1H),7.81–7.73(m, 1H),7.60(d,J=9.0Hz,3H),7.45–7.27(m,5H),7.23–7.12(m,3H),6.95–6.88(m,1H),2.80(d,J=4.8Hz,3H). 13 C NMR(100MHz,Chloroform-d)δ165.50,161.50,160.35,158.38,154.95,154.24,151.35,147.78,147.15,138. 81,137.27,131.77,129.83,121.59,119.48,119.19,115.35,113.63,112.42,112.05,110.15,109.10,26.32. 19 F NMR(376MHz,DMSO-d6)δ-110.60(t,J=8.4Hz,2F).HRMS(EI + )cal.for C 27 H 20 F2N4O5(M) + 518.1402, found 518.1433.
[0113] Example 5: Synthesis of 4-(4-(3-(3-((2,6-difluorophenyl)sulfonyl)phenyl)ureaoxy)-N-methylpicolinamide
[0114]
[0115] Reagents and conditions: a) Et3N, THF, DMAP, rt, 2h; b) BTC, Et3N, DCM, 0℃, 12h; c) DCM, Ar, 12h.
[0116] Experimental steps: 2,6-difluorobenzenesulfonyl chloride (1.1 equi) and m-diphenylamine were used as raw materials, 4-dimethylaminopyridine and anhydrous triethylamine were used as bases, and tetrahydrofuran was used as solvent. The reaction was carried out at room temperature for 2 hours to obtain a light yellow solid N-(3-aminophenyl)-2,6-difluorobenzenesulfonamide with a yield of 80%. 1H NMR (400MHz, DMSO-d6) δ10.51(s,1H),7.68(m,1H),7.25(t,J=9.2Hz,2H),6.84(t,J=8.0Hz,1H ), 6.36 (t, J = 2.0Hz, 1H), 6.28 (dd, J = 7.8, 2.0Hz, 1H), 6.22 (dd, J = 8.0, 2.0Hz, 1H), 5.15 (s, 2H). 19 F NMR (376MHz, DMSO-d6) δ-107.68 (dd, J=9.8, 6.0Hz).
[0117] The obtained N-(3-aminophenyl)-2,6-difluorobenzenesulfonamide (0.57 g, 2 mmol) was dissolved in anhydrous dichloromethane, and a mixture of 4-(4-isocyanate)-N-methylpicolinamide in anhydrous dichloromethane (10 mL) was slowly added dropwise, and the mixture was reacted at room temperature for 12 hours. After the reaction was completed, the solvent was removed under reduced pressure, and the mixture was purified by column chromatography (ethyl acetate: n-heptane = 1:1) to obtain a light yellow solid with a yield of 76%. 1 H NMR (400MHz, DMSO-d6) δ10.88(s,1H),8.85–8.72(m,3H),8.51(d,J=5.6Hz,1H),7.71(m,1H),7.57(d,J=9 .2Hz,2H),7.39(d,J=2.4Hz,1H),7.27(m,4H),7.16(m,4H),6.78(d,J=7.6Hz,1H),2.80(d,J=4.8Hz,3H). 13 C NMR(100MHz,Chloroform-d)δ165.36,161.50,159.13,154.57,154.50,148.04,146.52,138.22,138.05,1 37.06,133.22,127.86,121.59,119.53,118.98,118.32,117.23,115.35,113.08,110.97,110.37,26.33. 19 F NMR(376MHz,DMSO-d6)δ-107.63(dd,J=10.2,6.4Hz).HRMS(EI + )cal.forC 26 H 21 F2N5O5S(M) + 553.1231, found 553.1276.
[0118] Example 6: Synthesis of 4-(4-(3-(3-((2-fluorobenzyl)oxy)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0119] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0120] Experimental steps: The operation method is the same as that of Example 1 to obtain a white solid (1.25 g, 70%). 1 H NMR(400MHz,Chloroform-d)δ8.13(s,1H),7.46(ddt,J=8.0,2.2,1.0Hz,1H),7.43–7.34(m,2H),7.30(dd,J =8.4,7.6Hz,1H),7.24–7.12(m,3H),6.75(ddd,J=7.8,2.0,1.2Hz,1H),5.20(d,J=1.0Hz,2H),1.43(s,9H).
[0121] The above-obtained tert-butyl (3-((2-fluorobenzyl)oxy)phenyl)carbamate was dissolved in a mixture of trifluoroacetic acid and dichloromethane (1:1), stirred at room temperature for 2 hours, and then the solvent was removed under reduced pressure. Alkalinization was performed with sodium hydroxide, and extraction was performed with an organic solvent. The organic phases were combined, dried over anhydrous sodium sulfate, and purified by column chromatography (ethyl acetate: n-heptane = 1:2) to obtain a white solid with a yield of 80%. 1 H NMR(400MHz,Chloroform-d)δ7.43–7.35(m,2H),7.23–7.13(m,2H),7.11–7.04(m,1H),6.76(ddd,J=8.0,2. 0,1.2Hz,1H),6.52(t,J=2.0Hz,1H),6.43(ddd,J=8.0,2.0,1.2Hz,1H),5.22(s,2H),5.19(d,J=1.0Hz,2H).
[0122] 4-(4-isocyanate)-N-methylpicolinamide was dissolved in anhydrous dichloromethane (10 mL), and a dichloromethane mixture of 3-((2-fluorobenzyl)oxy)aniline (0.43 g, 2 mmol) was slowly added dropwise, and the mixture was reacted at room temperature for 12 hours. After the reaction was completed, the reaction solution was removed under reduced pressure and purified by column chromatography (ethyl acetate: n-heptane = 1:1), and the obtained product was a white solid. Yield: 70%. 1H NMR(400MHz,Chloroform-d)δ9.16(s,1H),8.94(s,1H),8.62(d,J=5.2Hz,1H),8.10(q ,J=4.8Hz,1H),7.58–7.53(m,3H),7.47(ddt,J=8.0,2.2,1.0Hz,1H),7.41–7.34(m,2H ),7.31(t,J=2.0Hz,1H),7.27–7.14(m,3H),7.04(dd,J=5.2,2.2Hz,1H),6.96–6.92(m ,2H),6.72(ddd,J=7.6,1.8,1.2Hz,1H),5.20(d,J=1.0Hz,2H),2.92(d,J=4.8Hz,3H). 13 C NMR(100MHz,Chloroform-d)δ165.50,161.50,161.22,159.19,154.71,154.30,149.01,147.78,138.84,138.22,129.88, 129.69,129.25,124.32,123.46,121.59,119.53,115.25,114.90,113.63,111.58,110.14,107.97,64.62,26.32.HRMS(EI + )cal.forC 27 H 23 FN4O4(M) + 486.1703, found 486.1768.
[0123] Example 7: Synthesis of 4-(4-(3-(3-((2-chlorobenzyl)oxy)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0124] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0125] Experimental steps: The operation method is the same as that of Example 1 to obtain a white solid (1.25 g, 70%). 1H NMR(400MHz,Chloroform-d)δ8.13(s,1H),7.46(ddt,J=8.0,2.2,1.0Hz,1H),7.43–7.34(m,2H),7.30(dd,J =8.4,7.6Hz,1H),7.24–7.12(m,3H),6.75(ddd,J=7.8,2.0,1.2Hz,1H),5.20(d,J=1.0Hz,2H),1.43(s,9H).
[0126] The obtained intermediate (3-((2-fluorobenzyl)oxy)phenyl)carbamic acid tert-butyl ester was dissolved in a mixture of trifluoroacetic acid and dichloromethane (1:1), and stirred at room temperature to remove Boc to obtain a white solid with a yield of 80%. 1 H NMR(400MHz,Chloroform-d)δ7.43–7.35(m,2H),7.23–7.13(m,2H),7.11–7.04(m,1H),6.76(ddd,J=8.0,2. 0,1.2Hz,1H),6.52(t,J=2.0Hz,1H),6.43(ddd,J=8.0,2.0,1.2Hz,1H),5.22(s,2H),5.19(d,J=1.0Hz,2H).
[0127] 4-(4-isocyanate)-N-methylpicolinamide and 3-((2-fluorobenzyl)oxy)aniline (0.43 g, 2 mmol) were used as raw materials and dichloromethane was used as solvent to react at room temperature for 12 hours. After the reaction was completed, the reaction solution was removed under reduced pressure and purified by column chromatography (ethyl acetate: n-heptane = 1:1). The obtained product was a white solid. Yield: 70%. 1 H NMR(400MHz,Chloroform-d)δ9.49(s,1H),8.95(s,1H),8.62(d,J=5.2Hz,1H ),8.10(q,J=4.8Hz,1H),7.58–7.54(m,3H),7.46–7.42(m,1H),7.38–7.31(m ,4H),7.28–7.23(m,2H),7.04(dd,J=5.2,2.2Hz,1H),6.96–6.92(m,2H),6.7 3(ddd,J=7.8,2.0,1.2Hz,1H),5.20(d,J=1.0Hz,2H),2.92(d,J=4.8Hz,3H). 13C NMR(100MHz,Chloroform-d)δ165.50,161.50,159.19,154.71,154.24,149.01,147.78,138.84,137.27,132.97,132. 47,129.69,129.25,129.18,125.78,121.59,119.53,114.90,113.08,111.58,110.15,107.97,68.71,26.32.HRMS(EI + )cal.for C 27 H 23 ClN4O4(M) + 502.1408, found 502.1490.
[0128] Example 8: Synthesis of 4-(4-(3-(3-((2-bromophenyl)oxy)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0129] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0130] Experimental steps: The operation method is the same as that of Example 1 to obtain tert-butyl (3-((2-bromobenzyl)oxy)phenyl)carbamate intermediate as a white solid with a yield of 70%. 1 H NMR(400MHz,Chloroform-d)δ8.15(s,1H),7.67–7.53(m,1H),7.44(ddd,J=8.4,2.0,1.2Hz,1H),7.37–7 .23(m,4H),7.12(t,J=2.0Hz,1H),6.74(ddd,J=7.8,2.0,1.2Hz,1H),5.20(d,J=0.6Hz,2H),1.44(s,9H).
[0131] Dissolve tert-butyl (3-((2-bromobenzyl)oxy)phenyl)carbamate in a mixture of trifluoroacetic acid and dichloromethane (1:1), and stir at room temperature to remove Boc to obtain a white solid with a yield of 78%. 1H NMR(400MHz,Chloroform-d)δ7.59–7.49(m,1H),7.40–7.26(m,3H),7.18(tt,J=7.5, 0.9Hz,1H),6.80–6.71(m,1H),6.45–6.40(m,2H),5.20(d,J=1.0Hz,2H),5.06(s,2H).
[0132] 4-(4-isocyanate)-N-methylpicolinamide and 3-((2-bromobenzyl)oxy)aniline (1 equiv) were used as raw materials and dichloromethane was used as solvent to react at room temperature for 12 hours. After the reaction was completed, the reaction solution was removed under reduced pressure and purified by column chromatography (ethyl acetate: n-heptane = 1:1). The product was obtained as a white solid. Yield: 70%. 1 H NMR(400MHz,Chloroform-d)δ9.17(s,1H),8.94(s,1H),8.62(d,J=5.2Hz,1H),8.07(q,J=4.8Hz,1H),7.57–7.53(m,4H),7.39–7.37(m,3H),7.2 8–7.22(m,3H),7.03(dd,J=5.2,2.2Hz,1H),6.96–6.91(m,2H),6.76(ddd,J=7.6,2.0,1.2Hz,1H),5.19(d,J=1.0Hz,2H),2.93(d,J=4.8Hz,3H). 13 C NMR(100MHz,Chloroform-d)δ165.36,161.50,159.19,154.70,154.50,148.04,146.30,138.84,138.22,133.79,131.78, 130.58,129.69,129.08,126.06,124.29,121.59,119.58,114.90,113.23,113.08,110.15,107.97,71.47,26.33.HRMS(EI + )cal.for C 27 H 23 BrN4O4(M) + 546.0903, found 546.0912.
[0133] Example 9: Synthesis of N-methyl-4-(4-(3-(3-((2-(trifluoromethyl)benzyl)oxy)phenyl)ureido)phenoxy)picolinamide
[0134]
[0135] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0136] Experimental steps: The operation method is the same as that of Example 1. The intermediate (tert-butyl 3-((2-(trifluoromethyl)benzyl)oxy)phenyl)carbamate is a white solid with a yield of 68%. 1 H NMR(400MHz,Chloroform-d)δ8.15(s,1H),7.67(dd,J=9.2,1.6Hz,1H),7.59–7.41(m,3H),7.37–7.22 (m,2H),7.11(t,J=2.0Hz,1H),6.72(ddd,J=7.6,1.8,1.2Hz,1H),5.20(d,J=1.0Hz,2H),1.43(s,9H).
[0137] Tert-butyl (3-((2-(trifluoromethyl)benzyl)oxy)phenyl)carbamate was dissolved in a mixture of trifluoroacetic acid and dichloromethane to remove the protecting group to obtain a white solid with a yield of 78%. 1 H NMR (400MHz, Chloroform-d) δ7.67 (dd, J=9.2, 1.5Hz, 1H), 7.55 (ddd, J=9.2, 6.8, 2.4 Hz, 1H), 7.45 (ddt, J=6.8, 2.3, 1.0Hz, 1H), 7.24 (td, J=6.8, 1.5Hz, 1H), 7.17 (t, J=7. 9Hz,1H),6.73(ddd,J=7.9,1.9,1.2Hz,1H),6.48(ddd,J=7.9,1.9,1.2Hz,1H),6.35( t,J=1.9Hz,1H),5.18(d,J=1.0Hz,2H),5.15(d,J=5.4Hz,1H),5.09(d,J=5.4Hz,1H).
[0138] Using 4-(4-isocyanate)-N-methylpicolinamide and 3-((2-(trifluoromethyl)benzyl)oxy)aniline as raw materials and dichloromethane as solvent, the final product was obtained by reaction at room temperature with a yield of 69%. 1H NMR(400MHz,Chloroform-d)δ9.14(s,1H),8.92(s,1H),8.62(d,J=5.2Hz,1H),8.07(q,J=4.8Hz,1H),7.64(dd,J=9.2,1.6Hz,1H),7.56–7.46(m,5H) ,7.37–7.22(m,4H),7.04(dd,J=5.2,2.4Hz,1H),6.98–6.91(m,2H),6.75( ddd,J=7.6,2.0,1.2Hz,1H),5.19(d,J=1.0Hz,2H),2.92(d,J=4.8Hz,3H). 13 C NMR(100MHz,Chloroform-d)δ165.36,161.50,159.21,155.56,154.50,148.04,146.61,138.84,137.27,132.82,129.69,129. 11,128.82,127.54,126.14,126.01,124.09,121.59,119.53,115.35,113.63,113.23,110.15,107.97,68.47,26.33.HRMS(EI + )cal.forC 28 H 23 F3N4O4(M) + 536.1671, found 536.1638.
[0139] Example 10: Synthesis of N-methyl-4-(4-(3-(3-((2-methylbenzyl)oxy)phenyl)ureido)phenoxy)picolinamide
[0140]
[0141] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0142] Experimental steps: The operation method is the same as that of Example 1 to obtain the intermediate (3-((2-methylbenzyl)oxy)phenyl)carbamic acid tert-butyl ester with a yield of 68%. 1H NMR(400MHz,Chloroform-d)δ8.13(s,1H),7.42(ddd,J=8.6,1.8,1.2Hz,1H),7.36–7.27(m,2H),7.24–7 .10(m,4H),6.77(ddd,J=7.8,2.0,1.2Hz,1H),5.11(d,J=1.0Hz,2H),2.36(d,J=0.6Hz,3H),1.43(s,9H).
[0143] The intermediate obtained in the previous step was dissolved in a mixture of trifluoroacetic acid and dichloromethane to remove the protecting group to obtain a white solid with a yield of 78%. 1 H NMR(400MHz,Chloroform-d)δ7.34–7.31(m,1H),7.22–7.11(m,4H),6.74(ddd,J=7.9,1.9,1.2Hz,1H),6.43(ddd,J=7.9, 1.9,1.2Hz,1H),6.33(t,J=1.9Hz,1H),5.22(d,J=5.4Hz,1H),5.13(d,J=5.4Hz,1H),5.06(d,J=1.0Hz,2H),2.35(s,2H).
[0144] The final product was obtained by reaction at room temperature with 4-(4-isocyanate)-N-methylpicolinamide and 3-((2-methylbenzyl)oxy)aniline as raw materials and dichloromethane as solvent. The yield was 71%. 1 H NMR(400MHz,Chloroform-d)δ9.16(s,1H),8.94(s,1H),8.62(d,J=5.2Hz,1H),8.10(q,J=4.8Hz,1H),7.59–7.53(m,3H),7.36–7.17(m,7H),7.04 (dd,J=5.4,2.2Hz,1H),6.96–6.91(m,2H),6.77(ddd,J=7.8,2.0,1.2Hz,1H),5.10(d,J=1.0Hz,2H),2.92(d,J=4.8Hz,3H),2.39(d,J=0.8Hz,3H). 13C NMR(100MHz,Chloroform-d)δ165.50,161.50,159.19,154.71,154.30,149.01,147.78,138.84,138.22,136.64,135.49,129 .69,129.57,129.16,126.93,124.03,122.06,119.53,114.82,113.63,111.58,110.23,107.98,69.36,26.32,19.64.HRMS(EI + )cal.forC 28 H 26 N4O4(M) + 482.1954, found 482.1932.
[0145] Example 11: Synthesis of 4-(4-(3-(3-((2-methoxybenzyl)oxy)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0146]
[0147] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0148] Experimental steps: The operation method is the same as that of Example 1 to obtain the intermediate (3-((2-methoxybenzyl)oxy)phenyl)carbamic acid tert-butyl ester with a yield of 68%. 1 H NMR(400MHz,Chloroform-d)δ8.14(s,1H),7.43(ddd,J=8.4,1.8,1.2Hz,1H),7.37–7.22(m,5H),6.99(td,J=7.6,1.2H z,1H),6.92(dd,J=7.4,1.2Hz,1H),6.74(ddd,J=7.8,2.0,1.2Hz,1H),5.05(d,J=1.0Hz,2H),3.88(s,3H),1.43(s,9H).
[0149] The intermediate obtained in the previous step was dissolved in a mixture of trifluoroacetic acid and dichloromethane to remove the protecting group to obtain a white solid with a yield of 78%. 1H NMR(400MHz,Chloroform-d)δ7.30(ddt,J=7.5,2.1,1.0Hz,1H),7.26–7.13(m,2H),7.00(td,J=7.6,1.3Hz,1H),6.92(dd,J=7.5,1.3H z,1H),6.76(ddd,J=7.9,1.9,1.2Hz,1H),6.45(ddd,J=8.0,1.9,1.2Hz,1H),6.35(t,J=1.9Hz,1H),5.17(s,2H),5.06(d,J=1.0Hz,2H).
[0150] 4-(4-isocyanate)-N-methylpicolinamide and 3-((2-methoxybenzyl)oxy)aniline were used as raw materials and dichloromethane was used as solvent. The final product was obtained by reaction at room temperature with a yield of 71%. 1 H NMR(400MHz,Chloroform-d)δ9.15(s,1H),8.94(s,1H),8.62(d,J=5.2Hz,1H),8.10(q,J=4.8Hz,1H),7.59–7.53(m,3H),7.36 –7.20(m,5H),7.04–6.92(m,5H),6.72(ddd,J=7.6,2.0,1.2Hz,1H),5.08(d,J=0.8Hz,2H),3.85(s,3H),2.92(d,J=4.8Hz,3H). 13 C NMR(100MHz,Chloroform-d)δ165.50,161.50,159.19,157.43,154.71,154.24,148.37,147.50,138.84,137.27,129.69,129 .18,128.64,125.53,123.55,121.98,119.48,114.90,113.98,111.90,111.58,110.15,107.97,65.71,55.49,26.32.HRMS(EI + )cal.for C 28 H 26 N4O5(M) + 498.1903, found 498.1983.
[0151] Example 12: Synthesis of 4-(4-(3-(3-((2-hydroxybenzyl)oxy)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0152]
[0153] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0154] Experimental steps: The operation method is the same as that of Example 1, and the intermediate is obtained as a white solid with a yield of 68%. 1 H NMR(400MHz,Chloroform-d)δ8.79(s,1H),8.13(s,1H),7.45–7.22(m,5H),7.09(td,J=8.2,2 .4Hz,1H),6.95(td,J=7.8,1.6Hz,1H),6.84–6.69(m,2H),5.07(d,J=1.0Hz,2H),1.43(s,9H).
[0155] The intermediate obtained in the previous step was dissolved in a mixture of trifluoroacetic acid and dichloromethane to remove the protecting group to obtain a white solid with a yield of 78%. 1 H NMR(400MHz,Chloroform-d)δ8.88(s,1H),7.27(ddt,J=7.8,2.4,1.0Hz,1H),7.17(t,J=7.8Hz,1H) ,7.12–6.95(m,2H),6.85–6.72(m,2H),6.48–6.34(m,2H),5.22(d,J=5.4Hz,1H),5.12–5.02(m,3H).
[0156] 4-(4-isocyanate)-N-methylpicolinamide and 2-((3-aminophenoxy)methyl)phenol were used as raw materials and dichloromethane was used as solvent. The final product was obtained by reaction at room temperature with a yield of 71%. 1 H NMR(400MHz,Chloroform-d)δ9.24(s,1H),9.16(s,1H),8.94(s,1H),8.62(d,J=5.2Hz,1H),8.10(q,J=4.8Hz,1H),7.58–7.52(m,3H) ,7.38–7.22(m,4H),7.05–6.92(m,5H),6.78(dd,J=8.2,1.6Hz,1H),6.73–6.70(m,1H),5.08(d,J=0.8Hz,2H),2.92(d,J=4.8Hz,3H). 13C NMR(100MHz,Chloroform-d)δ165.50,161.50,159.19,155.22,154.71,154.30,149.01,147.78,138.84,138.22,129.87, 129.69,129.41,127.42,123.31,121.59,119.53,115.62,114.90,113.63,111.58,110.14,107.97,66.87,26.32.HRMS(EI + )cal.for C 27 H 24 N4O5(M) + 484.1747, found 484.1789.
[0157] Example 13: Synthesis of 4-(4-(3-(benzyloxy)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0158] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0159] Experimental steps: The operation method is the same as that of Example 1, and the intermediate is obtained as a white solid with a yield of 68%. 1 H NMR (400MHz, Chloroform-d) δ8.12(s,1H),7.50–7.27(m,7H),7.21(t,J=2.0Hz,1H),6.71(ddd,J=7.6,2.0,1.2Hz,1H),5.07(t,J=1.0Hz,2H),1.43(s,9H).
[0160] The intermediate obtained in the previous step was dissolved in a mixture of trifluoroacetic acid and dichloromethane to remove the protecting group to obtain a white solid with a yield of 78%. 1 H NMR (400MHz, Chloroform-d) δ7.44–7.32(m,5H),7.18(t,J=7.8Hz,1H),6.75(ddd,J=7.8,2.0,1.2Hz,1H),6.43(ddd ,J=7.8,1.8,1.2Hz,1H),6.32(t,J=1.8Hz,1H),5.22(d,J=5.4Hz,1H),5.13(d,J=5.4Hz,1H),5.07(t,J=1.0Hz,2H).
[0161] The final product was obtained by reaction at room temperature with 4-(4-isocyanate)-N-methylpicolinamide and 3-(benzyloxy)aniline as raw materials and dichloromethane as solvent. The yield was 71%. 1 H NMR(400MHz,Chloroform-d)δ9.17(s,1H),8.94(s,1H),8.58(d,J=5.2Hz,1H),8.10(q,J=4.8Hz,1H),7.56–7.49(m,3H),7.41–7 .29(m,7H),7.23(dd,J=8.4,7.8Hz,1H),7.04(t,J=8.0Hz,1H),6.99–6.94(m,2H),5.06(t,J=1.0Hz,2H),2.92(d,J=4.8Hz,3H). 13 C NMR(100MHz,Chloroform-d)δ165.50,161.50,159.30,154.71,154.30,149.01,147.78,138.84,138.22,136.88, 129.69,128.35,128.08,127.98,122.27,119.57,114.82,114.01,111.58,110.23,107.98,70.05,26.32.HRMS(EI + )cal.for C 27 H 24 N4O4(M) + 468.1789, found 468.1756.
[0162] Example 14: Synthesis of N-methyl-4-(4-(3-(3-((2-nitrobenzyl)oxy)phenyl)ureido)phenoxy)picolinamide
[0163]
[0164] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0165] Experimental steps: The operation method is the same as that of Example 1, and the intermediate is obtained as a white solid with a yield of 67%. 1H NMR(400MHz,Chloroform-d)δ8.19–8.07(m,2H),7.64–7.40(m,4H),7.34–7.14 (m,2H),6.75(ddd,J=7.6,1.8,1.2Hz,1H),5.33(d,J=1.0Hz,2H),1.43(s,9H).
[0166] The intermediate obtained in the previous step was dissolved in a mixture of trifluoroacetic acid and dichloromethane to remove the protecting group to obtain a white solid with a yield of 78%. 1 H NMR(400MHz,Chloroform-d)δ8.12(dt,J=8.0,0.8Hz,1H),7.63–7.56(m,1H),7.51–7.44(m,2H),7.17(t,J=8.0Hz,1H),6.7 8(ddd,J=7.8,1.8,1.2Hz,1H),6.44(ddd,J=7.8,1.8,1.2Hz,1H),6.35(t,J=1.8Hz,1H),5.26(d,J=0.8Hz,2H),5.17(s,2H).
[0167] 4-(4-isocyanate)-N-methylpicolinamide and 3-((2-nitrobenzyl)oxy)aniline were used as raw materials and dichloromethane was used as solvent. The final product was obtained by reaction at room temperature with a yield of 71%. 1 H NMR(400MHz,Chloroform-d)δ9.17(s,1H),8.94(s,1H),8.62(d,J=5.2Hz,1H),8.17–8.05(m,2H),7.57–7.52(m,6H),7.37(ddd,J=8.4,2.0,1.2Hz,1H),7 .28–7.23(m,2H),7.03(dd,J=5.4,2.2Hz,1H),6.96–6.92(m,2H),6.72(ddd, J=7.8,2.0,1.2Hz,1H),5.30(qd,J=13.4,0.8Hz,2H),2.92(d,J=4.8Hz,3H). 13C NMR(100MHz,Chloroform-d)δ165.50,161.50,159.19,154.95,154.24,147.78,147.15,147.11,138.84,137.27,132.54, 129.91,129.69,128.39,127.85,125.04,121.59,119.48,115.35,113.63,111.58,110.15,107.97,68.12,26.32.HRMS(EI + )cal.forC 27 H 23 N5O6(M) + 513.1648, found 513.1679.
[0168] Example 15: Synthesis of 4-(4-(3-(3-((2-chloro-6-fluorobenzyl)oxy)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0169]
[0170] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0171] Experimental steps: The operation method is the same as that of Example 1, and the intermediate is obtained as a white solid with a yield of 66%. 1 H NMR(400MHz,Chloroform-d)δ8.13(s,1H),7.50–7.39(m,2H),7.38–7.22(m,3H),7.1 7(dd,J=8.0,1.2Hz,1H),6.74(ddd,J=7.8,2.0,1.2Hz,1H),5.24(s,2H),1.43(s,9H).
[0172] The intermediate obtained in the previous step was dissolved in a mixture of trifluoroacetic acid and dichloromethane to remove the protecting group to obtain a white solid with a yield of 78%. 1 H NMR(400MHz,Chloroform-d)δ7.49–7.34(m,2H),7.23–7.14(m,1H),7.02(dd,J=7.8,1.2 Hz,1H),6.76(ddd,J=7.8,2.0,1.2Hz,1H),6.51–6.41(m,2H),5.26(s,2H),5.17(s,2H).
[0173] The final product was obtained by reaction at room temperature with 4-(4-isocyanate)-N-methylpicolinamide and 3-((2-chloro-6-fluorobenzyl)oxy)aniline as raw materials and dichloromethane as solvent. The yield was 71%. 1 H NMR(400MHz,Chloroform-d)δ9.14(s,1H),8.92(s,1H),8.62(d,J=5.2Hz,1H),8.07(q,J =4.8Hz,1H),7.58–7.53(m,3H),7.42(t,J=7.8Hz,1H),7.38–7.34(m,2H),7.30(t,J=2.0 Hz,1H),7.25(t,J=8.0Hz,1H),7.14(dd,J=7.8,1.2Hz,1H),7.03(dd,J=5.3,2.2Hz,1H), 6.97–6.93(m,2H),6.72(ddd,J=7.6,1.9,1.2Hz,1H),5.26(s,2H),2.92(d,J=4.7Hz,3H). 13 C NMR(100MHz,Chloroform-d)δ165.50,161.50,161.04,159.19,154.70,154.24,148.37,147.78,138.84,137.27,132. 71,129.69,129.59,125.70,121.98,119.48,114.90,114.35,113.23,113.08,110.15,107.97,63.09,26.32.HRMS(EI + )cal.for C 27 H 22 ClFN4O4(M) + 520.1314, found 520.1345.
[0174] Example 16: Synthesis of 4-(4-(3-(3-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)phenyl)ureido)phenoxy)-N-methylpicolinamide
[0175]
[0176] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0177] Experimental steps: The operation method is the same as that of Example 1, and the intermediate is obtained as a white solid with a yield of 69%. 1H NMR(400MHz,Chloroform-d)δ8.18(s,1H),7.54–7.41(m,4H),7.37–7.26(m,1H) ,7.20–7.11(m,2H),6.73(ddd,J=7.7,1.9,1.2Hz,1H),5.31(s,2H),1.44(s,9H).
[0178] The intermediate obtained in the previous step was dissolved in a mixture of trifluoroacetic acid and dichloromethane to remove the protecting group to obtain a white solid with a yield of 78%. 1 H NMR(400MHz,Chloroform-d)δ7.54–7.42(m,2H),7.19(t,J=7.8Hz,1H),7.11(dd,J=6.8,1 .6Hz,1H),6.70(ddd,J=8.0,2.0,1.2Hz,1H),6.49–6.39(m,2H),5.30(s,2H),5.09(s,2H).
[0179] The final product was obtained by reaction at room temperature with 4-(4-isocyanate)-N-methylpicolinamide and 3-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)aniline as raw materials and dichloromethane as solvent. The yield was 71%. 1 H NMR(400MHz,Chloroform-d)δ9.14(s,1H),8.92(s,1H),8.62(d,J=5.2Hz,1H),8.07 (q,J=4.8Hz,1H),7.61(dd,J=9.2,1.2Hz,1H),7.56–7.53(m,3H),7.47–7.37(m,2H) ,7.29–7.23(m,2H),7.15(dd,J=7.2,1.2Hz,1H),7.04(dd,J=5.4,2.4Hz,1H),6.96– 6.92(m,2H),6.73(ddd,J=7.8,2.0,1.2Hz,1H),5.30(s,2H),2.93(d,J=4.8Hz,3H). 13 C NMR(100MHz,Chloroform-d)δ165.36,161.50,160.01,159.16,154.57,154.50,148.04,146.52,138.84,138.22,129.90,129. 69,128.17,123.30,122.98,121.59,121.20,119.45,116.74,115.35,113.63,113.37,110.37,107.97,64.24,26.33.HRMS (EI+ )cal.for C 28 H 22 F4N4O4(M) + 554.1577, found 554.1579.
[0180] Example 17: Synthesis of N-methyl-4-(4-(3-(3-((3-(trifluoromethyl)benzyl)oxy)phenyl)ureido)phenoxy)picolinamide
[0181]
[0182] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0183] Experimental steps: The operation method is the same as that of Example 1, and the intermediate is obtained as a white solid with a yield of 62%. 1 H NMR(400MHz,Chloroform-d)δ8.15(s,1H),7.81–7.66(m,2H),7.59–7.44(m,3H),7.30(dd,J=8.4,7 .8Hz,1H),7.12(d,J=1.8Hz,1H),6.72(ddd,J=7.8,2.0,1.2Hz,1H),5.24–5.05(m,2H),1.43(s,9H).
[0184] The intermediate obtained in the previous step was dissolved in a mixture of trifluoroacetic acid and dichloromethane to remove the protecting group to obtain a white solid with a yield of 78%. 1 H NMR(400MHz,Chloroform-d)δ7.76–7.72(m,1H),7.68(ddd,J=9.4,2.4,1.6Hz,1H),7.52–7.41(m,2H),7.19(t,J=7.8Hz,1H),6.7 3(ddd,J=8.0,2.0,1.2Hz,1H),6.48(ddd,J=7.8,2.0,1.2Hz,1H),6.33(t,J=1.8Hz,1H),5.15(d,J=5.4Hz,1H),5.14–5.06(m,3H).
[0185] The final product was obtained by reaction at room temperature with 4-(4-isocyanate)-N-methylpicolinamide and 3-((3-(trifluoromethyl)benzyl)oxy)aniline as raw materials and dichloromethane as solvent. The yield was 71%. 1H NMR(400MHz,Chloroform-d)δ9.14(s,1H),8.92(s,1H),8.62(d,J=5.2Hz,1H),8 .07(q,J=4.8Hz,1H),7.80–7.66(m,2H),7.60–7.54(m,5H),7.36(ddd,J=8.6,2. 0,1.2Hz,1H),7.30–7.24(m,2H),7.04(dd,J=5.2,2.4Hz,1H),6.98–6.92(m,2H) ,6.72(ddd,J=7.6,2.0,1.2Hz,1H),5.11(t,J=0.8Hz,2H),2.92(d,J=4.8Hz,3H). 13 C NMR(100MHz,Chloroform-d)δ165.36,161.50,159.32,155.56,154.50,148.04,146.61,138.84,137.27,135.44,132.20,129. 69,128.70,128.50,126.52,124.50,123.93,121.59,119.53,115.35,113.63,113.23,110.15,107.97,70.67,26.33.HRMS(EI + )cal.for C 28 H 23 F3N4O4(M) + 536.1671, found 536.1690.
[0186] Example 18: Synthesis of N-methyl-4-(4-(3-(3-((4-(trifluoromethyl)benzyl)oxy)phenyl)ureido)phenoxy)picolinamide
[0187]
[0188] Reagents and conditions: a) K2CO3, acetone, 0℃; b) TFA / DCM, rt, 2h; c) BTC, Et3N, DCM, 0℃, 12h; d) DCM, Ar, 12h.
[0189] Experimental steps: The operation method is the same as that of Example 1, and the intermediate is obtained as a white solid with a yield of 63%. 1H NMR(400MHz,Chloroform-d)δ8.15(s,1H),7.72–7.62(m,2H),7.52–7.40(m,3H),7.30(dd,J=8.5,7.7 Hz,1H),7.12(t,J=1.9Hz,1H),6.72(ddd,J=7.7,1.9,1.2Hz,1H),4.97(t,J=1.0Hz,2H),1.43(s,9H).
[0190] The intermediate obtained in the previous step was dissolved in a mixture of trifluoroacetic acid and dichloromethane to remove the protecting group to obtain a white solid with a yield of 78%. 1 H NMR(400MHz,Chloroform-d)δ7.73–7.63(m,2H),7.49–7.41(m,2H),7.19(t,J=7.8Hz,1H),6.73(ddd,J=7.8,1.8,1.2Hz,1H), 6.48(ddd,J=7.8,1.8,1.2Hz,1H), 6.33(t,J=1.8Hz,1H), 5.15(d,J=5.4Hz,1H), 5.09(d,J=5.4Hz,1H), 4.96(t,J=1.0Hz,2H).
[0191] The final product was obtained by reaction at room temperature with 4-(4-isocyanate)-N-methylpicolinamide and 3-((4-(trifluoromethyl)benzyl)oxy)aniline as raw materials and dichloromethane as solvent. The yield was 71%. 1 H NMR(400MHz,Chloroform-d)δ9.14(s,1H),8.92(s,1H),8.62(d,J=5.2Hz,1H ),8.07(q,J=4.8Hz,1H),7.65–7.60(m,2H),7.57–7.53(m,3H),7.49–7.45(m, 2H),7.37–7.34(m,1H),7.29–7.24(m,2H),7.04(dd,J=5.2,2.4Hz,1H),6.97– 6.92(m,2H),6.75–6.70(m,1H),4.98(t,J=1.0Hz,2H),2.92(d,J=4.8Hz,3H). 13C NMR(100MHz,Chloroform-d)δ165.36,161.50,159.32,155.56,154.50,148.04,146.61,138.84,137.27,136.59,131. 01,129.69,128.62,126.23,124.47,121.59,119.53,115.35,113.63,113.23,110.15,107.97,69.54,26.33.HRMS(EI + )cal.forC 28 H 23 F3N4O4(M) + 536.1671, found 536.1682.
[0192] The other compounds in Table 1 were prepared by similar methods to Examples 1-18.
[0193] Embodiment 19
[0194] 1. Antitumor activity test of the compounds of the present invention
[0195] 1. Experimental Principle
[0196] CCK8, or Cell Counting Kit-8, is a water-soluble tetrazolium salt based on WST (chemical name 2-(2-methoxy-4-nitrobenzene)-3-(4-nitrobenzene)-5-(2,4-disulfonylbenzene)-2H-tetrazolium monosodium salt). Dehydrogenases in living cells can react with CCK-8 to form yellow formazan compounds. The amount of formazan compound is proportional to the number of living cells. The absorbance value is read by a microplate reader. The more and faster the cell proliferation, the higher the absorbance value; the greater the cytotoxicity, the lower the absorbance value. Cell survival rate, proliferation rate, inhibition rate, reaction cell proliferation, drug toxicity to cells, etc. can be calculated. The application scope of CCK-8 includes: cell growth curve drawing, drug screening, cell proliferation assay, cytotoxicity assay, and tumor drug sensitivity test.
[0197] 2. Experimental steps
[0198] 1. Cell seeding plate: Digest the cells in logarithmic growth phase with trypsin and prepare a cell suspension. Add 100 μl to each well to make the cell density of each well 1000-5000. Fill the edge wells with sterile PBS. Cultivate at 5% CO2 and 37°C until the cells adhere to the wall and cover the bottom of the well.
[0199] 2. After culturing for 12 hours until the cells adhere to the wall, remove the original culture medium. Add different concentrations of the example compounds prepared in the culture medium (with 0.1% DMSO as a cosolvent), set up 4 parallel wells in total, and add 200 μl of culture medium to the control well without any drug;
[0200] 3. Incubate at 5% CO2, 37°C for 48 or 72 hours, and observe under a microscope. Add 10 μl of CCK-8 solution to each well, tap the culture plate gently to mix, and incubate in the incubator for 1-4 hours.
[0201] 4. Use an enzyme-labeled instrument to measure the light absorption value at 450nm and calculate the inhibition rate of the drug on cells according to the formula.
[0202] 3. Notes
[0203] 1. If you do not want to measure the OD value temporarily, add 10 μl of 0.1M HCl solution or 1% SDS (w / v) solution to each well and store it at room temperature away from light. If measured within 24 hours, the absorbance value will not change.
[0204] 2. If the substance to be tested is oxidizing or reducing, remove the old culture medium before adding CCK-8, wash twice with culture medium, and then add fresh culture medium to eliminate the influence.
[0205] 4. Results Analysis
[0206] Experimental group: absorbance values of cells and CCK-8 solution in the experimental group;
[0207] Negative control: absorbance values of control cells and CCK-8 solution;
[0208] Blank control: absorbance values of culture medium and CCK-8 solution;
[0209] Proliferation rate (cell viability) = (experimental group - blank control) / (negative control - blank control) × 100%
[0210] Inhibition rate (cytotoxicity) = 1-(experimental group-blank control) / (negative control-blank control) × 100%
[0211] IC 50 Value calculation: Linear regression between sample concentration and cell inhibition rate, and use software to calculate the half inhibitory concentration IC of the sample on cells 50 value.
[0212] Table 1 The half inhibitory concentration IC of the compounds on each cell 50 value.
[0213]
[0214]
[0215]
[0216]
[0217]
[0218]
[0219]
[0220]
[0221]
[0222]
[0223]
[0224]
[0225]
[0226]
[0227]
[0228]
[0229]
[0230] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A compound having a structure represented by general formula (I) or a pharmaceutically acceptable salt thereof; In the formula, Y is O; is unsubstituted or substituted phenyl, wherein the substitution refers to substitution by one or more substituents selected from the group consisting of halogen, amino, nitro, cyano, hydroxyl, carboxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl; or is a substituted or unsubstituted 4-10 membered heteroaryl group selected from the following structures: In various types, R 1 , R 2 , R 3 , R 4 Each independently selected from: H, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, nitro, F, Cl, Br, amino, hydroxyl; for In the formula, R 6 , R 7 , R 8 , R 9 All are hydrogen; for In the formula, R 10 , R 11 , R 12 , R 13 All are hydrogen; for R 14 , R 16 , R 17 All are hydrogen; R 15 For-CONR aa R bb , R aa For H, R bb C 1-4 alkyl; for 2. The compound according to claim 1, characterized in that is unsubstituted or substituted phenyl, wherein the substitution refers to substitution by one or more substituents selected from the group consisting of halogen, amino, nitro, hydroxyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy.
3. The compound according to claim 1, characterized in that It is unsubstituted or substituted phenyl, and the substitution refers to substitution by one or more substituents selected from the following group: fluorine, chlorine, bromine, amino, nitro, hydroxyl, methyl, ethyl, propyl, isopropyl, trifluoromethyl, pentafluoroethyl, heptafluoroisopropyl, methoxy, ethoxy, propoxy, isopropoxy.
4. The compound according to claim 1, characterized in that Ring A is In the formula, R a H, C 1-4 Haloalkyl, F, Cl, Br or methyl; R b H or C 1-4 Haloalkyl; R c H, C 1-4 haloalkyl, nitro, F, Cl, Br, methyl, methoxy, amino or hydroxy; R d H, C 1-4 haloalkyl, nitro, F, Cl, Br, methyl, methoxy, amino or hydroxy; R e H, C 1-4 Haloalkyl, nitro, F, Cl, Br, methyl, methoxy, amino or hydroxy.
5. The compound according to claim 4, characterized in that R b , R c , R d For hydrogen.
6. The compound according to claim 1, characterized in that is a substituted or unsubstituted 4-10 membered heteroaryl group selected from the following structures: In various types, R 1 , R 3 , R 4 H; R 2 H or C 1-4 alkyl.
7. The compound according to claim 1, characterized in that is a substituted or unsubstituted 4-10 membered heteroaryl group selected from the following structures: In various types, R 1 , R 2 , R 3 , R 4 As defined in claim 1.
8. The compound according to claim 1, characterized in that is a substituted or unsubstituted 4-10 membered heteroaryl group selected from the following structures: In various types, R 1 , R 3 , R 4 H; R 2 H or C 1-4 alkyl.
9. The compound according to any one of claims 1, 6 to 8, characterized in that R 1 , R 3 , R 4 H; R 2 It is H or methyl.
10. The compound according to claim 1, characterized in that R 15 It is -CONH-methyl.
11. The compound according to claim 1, characterized in that for 12. The compound according to claim 1, characterized in that The compound is any one of compounds numbered 1 to 96; 13. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the compound or pharmaceutically acceptable salt according to any one of claims 1 to 12; and a pharmaceutically acceptable carrier.
14. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1 to 12 or the pharmaceutical composition according to claim 13 for preparing an anti-tumor drug, wherein the tumor is selected from the group consisting of liver cancer, gastric cancer, and breast cancer.
Citation Information
Patent Citations
Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
CN101039932A
Diaryl urea compound and use thereof
CN101298427A
Substituted bisarylurea derivatives
CN1972925A
